Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition

Marcel Kemper; Georg Evers; Arik Bernard Schulze; Jan Sperveslage; Christoph Schülke; Georg Lenz; Thomas Herold; Wolfgang Hartmann; Hans-Ulrich Schildhaus; Annalen Bleckmann

doi:10.18632/oncotarget.28293

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition

PDF | How to cite

Oncotarget. 2022; 13:1216-1216. https://doi.org/10.18632/oncotarget.28293

Metrics: PDF 754 views | ?

Marcel Kemper^1,2,*, Georg Evers^1,2,*, Arik Bernard Schulze^1,2, Jan Sperveslage³, Christoph Schülke⁴, Georg Lenz^1,2, Thomas Herold⁵, Wolfgang Hartmann³, Hans-Ulrich Schildhaus^2,5,# and Annalen Bleckmann^1,2,6,#

¹Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Muenster, 48149 Muenster, Germany
²West German Cancer Center, Sites Muenster & Essen, 45147 Essen, Germany
³Gerhard-Domagk-Institute of Pathology, University Hospital Muenster, 48149 Muenster, Germany
⁴Institute of Clinical Radiology, University Hospital Muenster, 48149 Muenster, Germany
⁵Institute of Pathology, University Hospital Essen, 45147 Essen, Germany
⁶Department of Hematology/Medical Oncology, University Medical Center Goettingen, 37075 Goettingen, Germany
^*Authors share first authorship
^#Authors share last authorship

Published: November 2, 2022

Copyright: © 2022 Kemper et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: The authors obtained written informed consent from the patient to publish information and images.

Original article: Oncotarget. 2021; 12:1946–1952. DOI: https://doi.org/10.18632/oncotarget.28062

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28293

Publication Alerts

Post-Publication Promotion

Publication Discount

Addendum:

Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition